“KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s712. doi:10.25251/t4cqj323.